Literature DB >> 5157960

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

D Teitelbaum, A Meshorer, T Hirshfeld, R Arnon, M Sela.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5157960     DOI： 10.1002/eji.1830010406

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


× No keyword cloud information.
  104 in total

Review 1.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 2.  Degeneracy, as opposed to specificity, in immunotherapy.

Authors:  David A Hafler
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.

Authors:  R Aharoni; D Teitelbaum; O Leitner; A Meshorer; M Sela; R Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 4.  Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.

Authors:  Omar Khan; Rana Zabad; Christina Caon; Marina Zvartau-Hind; Alexandros Tselis; Robert Lisak
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 6.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

Review 7.  Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations.

Authors:  Eilhard Mix; Hans Meyer-Rienecker; Uwe K Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

8.  Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.

Authors:  C González-García; B Bravo; A Ballester; R Gómez-Pérez; C Eguiluz; M Redondo; A Martínez; C Gil; S Ballester
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

9.  Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms.

Authors:  Joel N H Stern; Zsolt Illés; Jayagopala Reddy; Derin B Keskin; Eric Sheu; Masha Fridkis-Hareli; Hiroyuki Nishimura; Celia F Brosnan; Laura Santambrogio; Vijay K Kuchroo; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

10.  A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.

Authors:  P G Schlegel; R Aharoni; Y Chen; J Chen; D Teitelbaum; R Arnon; M Sela; N J Chao
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.